Under the collaboration, the combination of Merck’s proprietary RSV antigen will be evaluated with NanoBio’s NanoStat adjuvant technology, for use as an intranasal vaccine.
As per the deal, Merck can negotiate a non-exclusive license to the NanoStat adjuvant for development of a commercial RSV vaccine.
According to NanoBio, NanoStat-adjuvanted RSV vaccine has demonstrated efficacy in inducing robust protective immunity, without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail.